InVivo BioTech Services

InVivo BioTech Services

Berlin, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

InVivo BioTech Services is an established, revenue-generating CDMO with over 25 years of experience, headquartered in Berlin, Germany. The company operates a dual business model, offering both contract manufacturing services (antibody/protein production, cell line development) and a proprietary portfolio of research-use-only diagnostic reagents, particularly focused on neuroscience biomarkers. Its core strengths lie in its ISO-certified facilities, deep expertise in mammalian cell culture, and a proven track record of producing components for FDA-approved diagnostic kits, positioning it as a reliable European partner for bioproduction needs.

Neurodegenerative Diseases

Technology Platform

Mammalian cell culture-based production platform for monoclonal antibodies and recombinant proteins, coupled with hybridoma and antibody characterization capabilities for reagent development.

Opportunities

Growth in the biologics CDMO market, especially in Europe, and increasing demand for high-quality research tools in neuroscience driven by global research into neurodegenerative diseases.
Potential to expand its proprietary reagent portfolio into new disease areas or develop more complex diagnostic assay components.

Risk Factors

Revenue dependency on a competitive and project-based CDMO market, regulatory compliance risks associated with manufacturing for regulated diagnostics, and competition from larger global CDMOs and reagent suppliers.

Competitive Landscape

Operates in the highly competitive global CDMO space, competing with large players like Lonza, Catalent, and Samsung Biologics on scale, and with other European niche CDMOs on specialization. In the reagent space, competes with large suppliers like Abcam, Bio-Techne, and Merck, as well as numerous smaller specialty antibody developers.